The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT04053972 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

377

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib

Sponsor

Sun Yat-sen University